Advertisement

Controlling the Risk of False Positive Clinical Trials

  • Ton J. Cleophas
  • Aeilko H. Zwinderman
Chapter

Abstract

Statistical hypothesis testing is much like gambling. If, with gambling once, your chance of a prize is 5%, then, with gambling 20 times, this chance will be close to 40%. The same is true with statistical testing of clinical trials. If, with one statistical test, your chance of a significant result is 5%, then after 20 tests, it will increase to 40%. This result is, however, not based on a true treatment effect, but, rather, on the play of chance. In current clinical trials, instead of a single efficacy-variable of one treatment, multiple efficacy-variables of more than one treatment are increasingly assessed. For example, in 16 randomized controlled trials with positive results, published in the British Medical Journal (BMJ) in 2004 (Table 8.1), the numbers of primary efficacy-variables varied from 4 to 13. This phenomenon introduces the statistical problem of multiple comparisons and multiple testing, which increases the risk of false positive results, otherwise called type I errors. There is no consensus within the statistical community on how to cope with this problem. Also, the issue has not been studied thoroughly for every type of variable. Clinical trials rarely adjust their data for multiple comparisons. For example, none of the underneath BMJ papers did. The current chapter briefly summarizes the main methods for control in order to further emphasize the importance of this issue, and it gives examples.

Keywords

British Medical Journal Less Significant Difference Honestly Significant Difference Statistical Hypothesis Testing Less Significant Difference Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Cleophas GM, Cleophas TJ (2003) Clinical trials in jeopardy. Int J Clin Pharmacol Ther 41:51–56PubMedGoogle Scholar
  2. Fuchs HA (1993) The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 20:1863–1866PubMedGoogle Scholar
  3. Furberg C (2002) To whom do the research findings apply? Heart 87:570–574PubMedCrossRefGoogle Scholar
  4. Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800–802CrossRefGoogle Scholar
  5. Julius S (2003) The ALHATT study: if you believe in evidence-based medicine. Stick to it. J Hypertens 21:453–454PubMedCrossRefGoogle Scholar
  6. Pocock SJ (1988) Clinical trials. A practical approach. Wiley, New YorkGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Ton J. Cleophas
    • 1
    • 2
  • Aeilko H. Zwinderman
    • 1
    • 3
  1. 1.Applied to Clinical TrialsEuropean Interuniversity College of Pharmaceutical MedicineLyonFrance
  2. 2.Department of MedicineAlbert Schweitzer HospitalDordrechtNetherlands
  3. 3.Department of Biostatistics and EpidemiologyAcademic Medical CenterAmsterdamNetherlands

Personalised recommendations